Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Sclerosis Relapse Clear all

Conditions: Multiple Sclerosis
Interventions: Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 16
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 13 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Buffalo, New York • Cleveland, Ohio + 1 more

Conditions: Multiple Sclerosis
Interventions: BG00002-E (natalizumab high titer); Biological
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 13
States / cities: Washington D.C., District of Columbia • Maitland, Florida • Miami, Florida + 10 more

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis
Interventions: Closed Loop Trans-Auricular Vagus Nerve Stimulation System, Placebo; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta-1b (Betaseron, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 51
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 47 more

Conditions: Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
Interventions: Autologous HB-adMSCs; Drug
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions: Acute Intermittent Hypoxia, Sham-Acute Intermittent Hypoxia; Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control; Drug · Procedure · Other
Lead sponsor: Jeffrey Gelfand; Other
Eligibility: 18 Years to 60 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Ocrelizumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Relapsing Multiple Sclerosis
Interventions: Tolebrutinib, Teriflunomide, Placebo to match Tolebrutinib, Placebo to match Teriflunomide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 23
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 18 more

Conditions: Relapse Remitting Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions: liothyronine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 58 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: MS Care Platform (icobrain ms and icompanion ms); Device
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Golden Valley, Minnesota • Hackensack, New Jersey • Neptune City, New Jersey

Conditions: Multiple Sclerosis, Acute Relapsing
Interventions: rHIgM22, Placebo; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: Long Beach, California • Sacramento, California • San Francisco, California + 8 more

Conditions: Multiple Sclerosis
Interventions: Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Fingolimod, Disease Modifying therapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 122
States / cities: Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 111 more

Conditions: Multiple Sclerosis
Interventions: Interferon-beta-1a FBS-free/HSA-free; Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Relapsing Multiple Sclerosis
Interventions: Atacicept 25 mg, Atacicept 75 mg, Atacicept 150 mg; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: Phoenix, Arizona • Northbrook, Illinois • East Lansing, Michigan + 3 more

Conditions: Multiple Sclerosis
Interventions: Ublituximab, Placebo; Biological · Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Pasadena, California • Torrance, California + 9 more

Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions: KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen; Biological · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
Interventions: KITE-363, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Newport Beach, California • Palo Alto, California • New York, New York + 2 more

Conditions: Multiple Sclerosis
Interventions: ofatumumab with PRF, ofatumumab with AI; Combination Product
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Fullerton, California • Aurora, Colorado • Basalt, Colorado + 9 more

Conditions: Multiple Sclerosis
Interventions: Copaxone®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 861 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: Cullman, Alabama • Carmichael, California • Atlanta, Georgia + 11 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Blood Draw, Lumbar Puncture; Procedure
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

Avonex 15 Year Long Term Follow-up Study

Natalizumab High Titer Immunogenicity and Safety

Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose

"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

Intermittent Hypoxia in Persons With Multiple Sclerosis

Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

Early Versus Delayed Start of Ocrevus Zunovo for Relapsing Multiple Sclerosis

Open-label Study of Liothyronine in MS

Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis

Atacicept in Multiple Sclerosis Extension Study, Phase II

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)